Liraglutide
Also known as: Victoza · Saxenda · Ablymico · Liraglutide STADA
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, liraglutide is indicated for weight management, and for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. For weight management, the product Saxenda is indicated in the European Union as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index of 30 kg/m² or more, or 27 to less than 30 kg/m² with at least one weight-related comorbidity. Saxenda is also indicated in the European Union for adolescents aged 12 years and above with obesity and a body weight above 60 kg. The product Victoza is indicated in the European Union for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate, or in addition to other medicinal products. In the United States, liraglutide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
From: Source: European Medicines Agency (EMA), Ablymico — EPAR, 25/08/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Liraglutide STADA — EPAR, 25/08/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA), Saxenda — EPAR, 31/07/2025. © European Medicines Agency. · Source: European Medicines Agency (EMA), Victoza — EPAR, 16/01/2026. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 475968 liraglutide
- EMA
- EMEA/H/C/001026, EMEA/H/C/003780, EMEA/H/C/006620, EMEA/H/C/006615
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Ablymico
Treatment of weight management.
Source: European Medicines Agency (EMA), Ablymico — EPAR, 25/08/2026. © European Medicines Agency.
Document date: 25/08/2026 · Official document →
FDA (USA) Liraglutide
1 INDICATIONS AND USAGE Liraglutide Injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use : Liraglutide Injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Limitations of Use : Coadministration with other liraglutide-containing products is not recommended.
Data provided by the U.S. Food and Drug Administration.
Document date: 20260727 · Official document →
EMA (EU) Liraglutide STADA
Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise
Source: European Medicines Agency (EMA), Liraglutide STADA — EPAR, 25/08/2026. © European Medicines Agency.
Document date: 25/08/2026 · Official document →
EMA (EU) Saxenda
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of • ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. Adolescents (≥12 years) Saxenda can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with: obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points)* and body weight above 60 kg. Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. *IOTF BMI cut-off points for obesity by sex between 12-18 years, in accordance with study design of the Trial 4180, see section 5.1. Children (6 to <12 years)Saxenda is indicated as an adjunct to healthy nutrition and increased physical activity for weight management in children from the age of 6 to <12 years with - obesity (BMI ≥95th percentile)* and- body weight ≥45 kgTreatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose. *CDC BMI cut-off points for obesity (≥95th percentile) by sex between 6 to <12 years, in accordance with study design of the Trial 4392, see section 5.1.
Source: European Medicines Agency (EMA), Saxenda — EPAR, 31/07/2025. © European Medicines Agency.
Document date: 31/07/2025 · Official document →
EMA (EU) Victoza
Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes. For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.
Source: European Medicines Agency (EMA), Victoza — EPAR, 16/01/2026. © European Medicines Agency.
Document date: 16/01/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Type 2 diabetes Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Liraglutide approved for in the European Union?
Treatment of weight management. (Source: European Medicines Agency (EMA), Ablymico — EPAR, 25/08/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- Data provided by the U.S. Food and Drug Administration.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Ablymico — EPAR, 25/08/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Liraglutide STADA — EPAR, 25/08/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Saxenda — EPAR, 31/07/2025. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Victoza — EPAR, 16/01/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.